Lymphoma

CPI-613 Gets Orphan Drug Designation for Peripheral T-Cell Lymphoma

By August 17, 2018

This first-in-class drug was previously granted Orphan Drug designation for the treatment of pancreatic cancer, acute myeloid leukemia, Burkitt lymphoma, and myelodysplastic syndromes.

CAR-T Therapy Kymriah Approved for Relapsed/Refractory Large B-Cell Lymphoma

By May 02, 2018

Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular expansion and persistence.

Adcetris + Chemo OK'd as Frontline Tx for Advanced Classical Hodgkin Lymphoma

By March 20, 2018

FDA approval was based on positive results from the Phase 3 ECHELON-1 trial.